Zeta Research Srl

Trieste, Italy

Zeta Research Srl

Trieste, Italy
SEARCH FILTERS
Time filter
Source Type

Mansi N.,Science di Otorinolaringoiatria della A.O.R.N. Santobono Pausilipon di Naples | D'Agostino G.,Science di Otorinolaringoiatria della A.O.R.N. Santobono Pausilipon di Naples | Scire A.S.,Zeta Research Srl | Morpurgo G.,Zeta Research Srl | And 2 more authors.
Indian Journal of Otolaryngology and Head and Neck Surgery | Year: 2014

Allergic rhinitis (AR) underlies many symptoms and complications which severely affect children’s quality of life. This two-arm study aimed at evaluate the efficacy and safety of the medical device Narivent® versus topical corticosteroids in the symptomatic management of allergic rhinitis in paediatric patients. A randomized study was conducted. Forty subjects with a diagnosis of allergic rhinitis were randomized to receive one puff of Narivent® into each nostril twice daily for 30 days (n = 20) or to receive one puff of topical intranasal corticosteroid into each nostril twice daily for 30 days (n = 20). In both treatment arms, severity of major symptoms related to AR, including nasal congestion, rhinorrhoea, sneezing and nasal itching, was assessed subjectively on a 0–100 mm visual analogue scale. Nasal congestion, rhinorrhoea and sneezing improved significantly after 30 days of treatment with Narivent®. Similarly, in topical steroids group severity of all subjective symptoms decreased significantly. Narivent® appears to be efficacious in treating nasal congestion and other major symptoms in children with AR over a 30-day period, showing comparable results to intranasal corticosteroids therapy but with a better safety profile. © 2014, Association of Otolaryngologists of India.


Schillani G.,University of Trieste | Foltran F.,University of Padua | Scire A.S.,Zeta Research Srl | Morpurgo G.,Zeta Research Srl | Gregori D.,University of Padua
Open Medical Devices Journal | Year: 2012

Rationale and aim: Nasal congestion is a common symptom in allergic and non-allergic rhinitis, rhinosinusitis and nasal polyposis. Although various pharmacotherapy options exist, no agent is universally efficacious. The aim of this study was to evaluate the clinical effectiveness efficacy of Narivent®, which is an osmotically acting medical device with anti-oedematous and anti-inflammatory effects, in a long-term (30 days) treatment. Methods: A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian Otolaryngology Department of 56 both genders patients with persistent nasal congestion. Patients received 2 puffs of Narivent® into each nostril 2 times a day over the course of 4 weeks. The severity of symptoms was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS) and the presence/absence of symptoms and signs. Differences in subjective and objective severity measures before and after treatment were compared using Paired-Sample Wilcoxon Signed Rank Test. Results: A significant improvement after treatment (p<0.001) has been recorded for the main subjective symptoms and objective signs (overall symptom burden, nasal congestion, cephalea, rhinorrhea, hyposmia, turbinates hypertrophy, mucosa status). Conclusion: Study results confirm the efficacy of Narivent® in treating nasal congestion over a 4 weeks period. © Damiani et al.


Mansi N.,Science di Otorinolaringoiatria della A.O.R.N. Santobono Pausilipon di Naples | D'Agostino G.,Science di Otorinolaringoiatria della A.O.R.N. Santobono Pausilipon di Naples | Scire A.S.,Zeta Research Srl | Morpurgo G.,Zeta Research Srl | Gregori D.,University of Padua
Open Medical Devices Journal | Year: 2012

Rationale and aim: Allergic rhinitis (AR) is a common disorder that affects people of all ages, peaking in childhood and in the teenage years. Although AR is not a serious disease, it is clinically relevant because underlies many symptoms and complications which severely affect children's quality of life. The aim of this study was to evaluate the clinical effectiveness of Narivent®, an osmotically acting medical device with anti-oedematous and anti-inflammatory effects, in the treatment of symptoms associated with allergic rhinitis in a paediatric population. Methods: A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian Otolaryngology Department of 20 both genders children with allergic rhinitis. Patients received 1 puff of Narivent® into each nostril 2 times a day over the course of 4 weeks. The severity of major symptoms associated with AR, such as nasal congestion, rhinorrhoea, sneezing and nasal itching, was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS). Differences in subjective severity measures before and after treatment were compared using Paired-Sample Wilcoxon Signed Rank Test. Results: Nasal congestion, rhinorrhoea and sneezing significantly improve after treatment (p<0.001). Conclusion: Study results confirm the efficacy of Narivent® in the treatment of nasal congestion and other major symptoms in children with AR over a 4 weeks period. © Mansi et al.


Vicheva D.,Medical university-Plovdiv | Schillani G.,University of Trieste | Morpurgo G.,Zeta Research Srl | Scire A.S.,Zeta Research Srl | Gregori D.,University of Padua
Open Medical Devices Journal | Year: 2012

Rationale and aim: Upper airway disorders, like allergic and non-allergic rhinitis, are common nasal conditions affecting millions of individuals worldwide. The prevalence of allergic rhinitis (AR), in particular, has been increasing in the last decades. The pervasiveness of this disorder therefore imposes a large burden both on individual patients and the society. A wide range of drugs exists for symptomatic treatment of rhinitis, such as corticosteroids, decongestants, and antihistamines, but standard therapies are often associated with several side effects. A new class of medical devices, based on bio-mechanically innovative triggers, has been proven to have a good clinical effectiveness with lower adverse reactions, particularly over prolonged administration periods. The present study aims at evaluating the economic impact of rhinitis, with respect to direct and indirect costs, and analysing the use of the medical device Narivent® compared to standard therapies to manage the symptoms of this illness. Methods: Via a Monte Carlo simulation study, data on disease prevalence, drug prescription and cost of both the specific therapeutic approach and the adverse events treatment will be combined to provide an estimate of the overall cost of the pharmacotherapy as compared with Narivent®. Results: Lowering the impact of adverse reactions related to standard therapy through the use of novel therapeutic approaches like Narivent®, might reduce the overall burden of rhinitis by about 5 billion per year. Conclusion: The use of the medical device Narivent®, as an alternative approach to manage symptoms associated with rhinitis, may contribute to bring down its costs by about 3.5% yearly as compared to the standard therapy. © Damiani et al.


Schillani G.,University of Trieste | Foltran F.,University of Padua | Scire A.S.,Zeta Research Srl | Morpurgo G.,Zeta Research Srl | Gregori D.,University of Padua
Open Medical Devices Journal | Year: 2012

Rationale and aim: Nasal congestion is a common symptom in rhinologic diseases such as rhinosinusitis, nasal polyposis and adenoid pathology. Although various pharmacotherapy options exist, no agent is universally efficacious. The aim of this study was to evaluate the efficacy of Narivent®, an osmotically acting medical device with antioedematous and anti-inflammatory effects, in a short-term (7days) treatment. Methods: A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian Otolaryngology Department of 36 both genders patients with nasal congestion. Patients received 2 puffs of Narivent® into each nostril 2 times a day over the course of 1 week. The severity of symptoms was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS) and the presence/absence of symptoms and signs. Differences in subjective and objective severity measures before and after treatment were compared using Paired-Sample Wilcoxon Signed Rank Test. Results: A significant improvement after treatment (p<0.001) has been recorded for the main subjective symptoms and objective signs (overall symptom burden, nasal congestion, cephalea, turbinates hypertrophy, normal mucosa status). Conclusion: Study results confirm the efficacy of Narivent® in treating nasal congestion over a 1 week period. © Damiani et al.


PubMed | Zeta Research Srl, University of Padua, Maulana Azad Medical College and LN and Science di Otorinolaringoiatria della A.O.R.N. Santobono Pausilipon di Naples
Type: Journal Article | Journal: Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India | Year: 2015

Allergic rhinitis (AR) underlies many symptoms and complications which severely affect childrens quality of life. This two-arm study aimed at evaluate the efficacy and safety of the medical device Narivent() versus topical corticosteroids in the symptomatic management of allergic rhinitis in paediatric patients. A randomized study was conducted. Forty subjects with a diagnosis of allergic rhinitis were randomized to receive one puff of Narivent() into each nostril twice daily for 30days (n=20) or to receive one puff of topical intranasal corticosteroid into each nostril twice daily for 30days (n=20). In both treatment arms, severity of major symptoms related to AR, including nasal congestion, rhinorrhoea, sneezing and nasal itching, was assessed subjectively on a 0-100mm visual analogue scale. Nasal congestion, rhinorrhoea and sneezing improved significantly after 30days of treatment with Narivent(). Similarly, in topical steroids group severity of all subjective symptoms decreased significantly. Narivent() appears to be efficacious in treating nasal congestion and other major symptoms in children with AR over a 30-day period, showing comparable results to intranasal corticosteroids therapy but with a better safety profile.


Vecchio M.G.,Prochild ONLUS | Berchialla P.,University of Turin | Didier N.,Sociedad Pino y Didier ltd | Cayul O.,Sociedad Pino y Didier ltd | And 3 more authors.
Open Obesity Journal | Year: 2013

The prevalence of obesity and overweight in children and adolescents during the last decades has reached the epidemic level in both developed and in developing countries. Besides the genetic aspects, which represent one of the motivating factors in the progress of obesity, the shift in the energetic balance also plays a significant role in the development of obesity. TV viewing and the high-calorie snack foods consumption have come under more scrutiny as potential causes of increased obesity in children and adolescents. The aim of the present work was to develop an instrument that allows to estimate the Chilean children's brand awareness. We developed the IBAI (International Brand Awareness Instrument), an age-appropriate instrument that uses twelve sheets with pictures of food logos to test children's recall and recognition. The IBAI was presented to a sample of 80 children aged from 3 to 10 years, enrolled in the city of Santiago de Chile. The instrument allowed distinguishing different kinds of children's brand awareness. Considering the total score reached by each child, the majority of the children for both genders showed a medium-low brand awareness (32.5%) followed by medium-high brand awareness (31.3%), high brand awareness (23.8%) and low brand awareness (12.5%). Although the study confirmed the moderate brand logo recognition in the children tested, it did not demonstrate a close relationship between this and the children's reported eating behaviors, food knowledge and preferences. © Vecchio et al.


Franchin L.,ZETA Research Srl | Zobec F.,ZETA Research Srl | Ghidina M.,ZETA Research Srl | Stefanini G.,ZETA Research Srl | And 2 more authors.
Progress in Nutrition | Year: 2012

The aim of the present work was to develop an instrument that allows to estimate the Italian children's brand awareness. We developed the IBAI (International Brand Awareness Instrument), an age-appropriate instrument that uses thirty sheets with pictures of food logos to test children's recall and recognition, and the IBAI-r, a reduced and less time-consuming form of the IBAI (with 12 sheets).The IBAI was presented (Study 1) to a sample of 145 children aged from 6 to 11 years, and after one month the IBAI-r was presented (Study 2) to the same sample. Both instruments allowed to distinguish different kinds of children's brand awareness and when compared, they resulted to be very consistent.


Gregori D.,University of Padua | Ballali S.,Prochild ONLUS | Vecchio M.G.,Prochild ONLUS | Contreras L.M.V.,Catholic University Cardinal Raúl Silva Henríquez | And 9 more authors.
Open Obesity Journal | Year: 2013

Nutrition labelling on food products represents an important tool for promoting healthy eating in consumers, and to guarantee transparency and clarity on products' characteristics. In an ideal scenario, consumers' better understanding and subsequently better compliance to nutritional facts would result in healthier choices, which could lead to an improved diet and to a reduction in disease-related risk factors. Research is necessary not only in assessing consumers' preferences towards different labels formats, but also to evaluate their ability to process food labels and their disposition towards new regulations concerning labelling. In our study, an ad-hoc survey was conducted to assess general knowledge and use of different labels and nutrition fact information in a Chilean sample (n= 1280), which was interviewed through a phone survey, performed over a 1-month period, in September 2012. The major part of the interviewees did not habitually read the labels and showed a low interest in paying an additional fee for additional information (89%). The rest was willing to pay an additional fee of the 5%, in order to get information expressed as Kcal per portion in 68% of cases compared to per 100g. Chilean consumers appeared to be interested to nutritional matters and considered nutritional labelling as a proper tool to achieve a healthy lifestyle. Considering the Chilean low knowledge on nutritional labelling, it is necessary to improve nutrition messages and nutrition knowledge among the Chilean population through fast action, especially to help consumers to make health-conscious choices. © Gregori et al.

Loading Zeta Research Srl collaborators
Loading Zeta Research Srl collaborators